EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Vergleichsstudie

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

Paolo A Ascierto iD, Michele Del Vecchio, Barbara Merelli, Helen Gogas, Ana M Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Caroline Gaudy-Marqueste, Jacopo Pigozzo, Iván Márquez-Rodas, Marcus O Butler und 17 weitere

New England Journal of Medicine · 2026

DOI: 10.1056/nejmoa2504966 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, 2026. Verfasst von Paolo A Ascierto und 28 weiteren Autor:innen. Beteiligte Einrichtung: Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy. Hauptthemen laut MEDLINE: Ipilimumab, Melanoma, Neoplasm Recurrence, Local, Nivolumab. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IpilimumabMelanomaNeoplasm Recurrence, LocalNivolumabSkin NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDisease-Free SurvivalFollow-Up StudiesImmune Checkpoint InhibitorsInfusions, IntravenousKaplan-Meier EstimateNeoplasm StagingChemotherapy, AdjuvantDouble-Blind MethodAdolescentYoung Adult

Substanzen

Immune Checkpoint InhibitorsIpilimumabNivolumab

Autor:innen und Institutionen

  • Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy.
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII Bergamo, Bergamo, Italy.
  • National and Kapodistrian University of Athens, Athens.
  • Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona.
  • Hospices Civils de Lyon, Pierre-Bénite, France.

ORCID-Profile: Paolo A Ascierto

Förderung

  • Bristol Myers Squibb

Zitieren

APA

Ascierto, P. A., Del Vecchio, M., Merelli, B., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Gaudy-Marqueste, C., Pigozzo, J., Márquez-Rodas, I., Butler, M. O., Di Giacomo, A. M., Gligich, O., De La Cruz-Merino, L., Arenberger, P., Atkinson, V., Nathan, P., Hill, A., …, & Larkin, J. (2026). Nivolumab for Resected Stage III or IV Melanoma at 9 Years. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2504966

Vancouver

Ascierto PA, Del Vecchio M, Merelli B, Gogas H, Arance AM, Dalle S, et al. Nivolumab for Resected Stage III or IV Melanoma at 9 Years. New England Journal of Medicine. 2026. doi:10.1056/nejmoa2504966

BibTeX
@article{Ascierto2026,
  author = {Ascierto, Paolo A and Del Vecchio, Michele and Merelli, Barbara and Gogas, Helen and Arance, Ana M and Dalle, Stéphane and Cowey, Charles Lance and Schenker, Michael and Gaudy-Marqueste, Caroline and Pigozzo, Jacopo and Márquez-Rodas, Iván and Butler, Marcus O and Di Giacomo, Anna Maria and Gligich, Oleg and De La Cruz-Merino, Luis and Arenberger, Petr and Atkinson, Victoria and Nathan, Paul and Hill, Andrew and Millward, Michael and Fecher, Leslie A and Khushalani, Nikhil I and Queirolo, Paola and Soomro, Raheela and Rathod, Dhanrajsinh and Askelson, Margarita and Pe Benito, Melanie and Joseph, Devanand and Larkin, James},
  title = {Nivolumab for Resected Stage III or IV Melanoma at 9 Years},
  journal = {New England Journal of Medicine},
  year = {2026},
  doi = {10.1056/nejmoa2504966}
}
Kostenlos starten →